NR3C2 and renal fibrosis: Currently, clinically approved drugs for renal fibrosis include RAS blockers (Ruiz-Ortega et al. 2020), the third-generation mineralocorticoid receptor antagonist finerenone (Grune et al. 2018) and SGLT2 inhibitors (canagliflozin and dapagliflozin).